TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, and value analysis committee staff. The company was founded in 2009 and is headquartered in Westminster, Colorado.…
TriSalus Life Sciences to Participate in the 38th Annual Piper Sandler Healthcare Conference on December 1, 2026
TriSalus Life Sciences (NASDAQ: TLSI) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 102 employees.
The shares were at 2.320 USD on 20 November 2026, down 47.2% over 52 weeks. Its 52-week range is 2.165 USD to 7.950 USD: the price is 70.8% below the high and 7.2% above the low.
Its market capitalisation is 143.14M USD.
TriSalus Life Sciences reports return on equity of 115.8%, an operating margin of -63.0% and revenue up 11.3% year over year.
It holds more cash than debt, a net cash position of 7.37M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 5 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 7.800 USD is 236.2% above the current price. The next earnings report is expected on 4 March 2027.